REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Completed · Phase 1 · Has a placebo group

Conditions studied: COVID19, ARDS

In brief

To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.

Key facts

Study ID

NCT04468971

Run by

Cellenkos, Inc.

People needed

45

Starts

2020-09-29

Expected to finish

2021-10-22

Last updated by the study team

2022-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented to have an RT-PCR-based diagnosis of SARS-CoV-2 infection by RT-PCR
• Moderate-to-severe ARDS as defined by the Berlin Criteria: ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of 200 mm Hg or less assessed with a positive end-expiratory pressure (PEEP) of >5 cm H2O.
• Intubated for less than 120 hours
• Age ≥18 years
• Ability to provide informed consent or duly appointment health care proxy with the authority to provide informed consent.

You may not qualify if…

• In the opinion of the investigator, unlikely to survive for >48 hours from screening.
• Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study.
• Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV).
• Females who are pregnant.
• Patients with active bacteremia at start of therapy enrollment or concurrently active moderate to severe other infectious which in the opinion of the investigator may possibly affect the safety of CK0802 treatment.
• Patients who have been intubated for more than 120 hours.
• Known hypersensitivity to DMSO or to porcine or bovine protein.
• Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of CK0802 treatment.
• High dose steroids.
• Receiving an investigational cellular therapy agent.

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States
• Columbia University — New York, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• Wake Forest University — Winston-Salem, North Carolina, United States
• Baylor College of Medicine, St Luke's Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.